Công thức Đông y Trung Quốc 01 cho ung thư vòm họng (NPC01) trong điều trị ung thư đầu và cổ và chất lượng cuộc sống liên quan đến sức khỏe: một nghiên cứu hồi cứu

Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008;371:1695–709.

Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005;365:2041–54.

Pfister DG, Spencer S, Adelstein D, Adkins D, Darlow SD. Head and neck cancers, version 2.2020, nccn clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2020:18(7);873–98.

Tshering Vogel DW, Zbaeren P, Thoeny HC. Cancer of the oral cavity and oropharynx. Cancer Imaging. 2010;10:62–72.

Sung H, Ferlay J, Siegel RL. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Lo Nigro C, Denaro N, Merlotti A, Merlano M. Head and neck cancer: improving outcomes with a multidisciplinary approach. Cancer Manag Res. 2017;9:363–71.

Pulte D, Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist. 2010;15:994–1001.

Ma BB, Hui EP, Wong SC, Tung SY, Yuen KK, et al. Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma--correlation with excision repair cross-complementing-1 polymorphisms. Ann Oncol. 2009;20:1854–9.

Ngan RK, Yiu HH, Lau WH, Yau S, Cheung FY, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol. 2002;13:1252–8.

Rogers SN, Semple C, Babb M, Humphris G. Quality of life considerations in head and neck cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016;130:S49–52.

Ojo B, Genden EM, Teng MS, Milbury K, Misiukiewicz KJ, et al. A systematic review of head and neck cancer quality of life assessment instruments. Oral Oncol. 2012;48:923–37.

Scott B, Butterworth C, Lowe D, Rogers SN. Factors associated with restricted mouth opening and its relationship to health-related quality of life in patients attending a maxillofacial oncology clinic. Oral Oncol. 2008;44:430–8.

Yanwei L, Yinli Y, Pan Z. Traditional herbal formula NPC01 exerts Antiangiogenic effects through inhibiting the PI3K/Akt/mTOR signaling pathway in nasopharyngeal carcinoma cells. Evid Based Complement Alternat Med. 2018;2018:5291517.

Nagasawa M. [consideration for the relation between a book of prescriptions of Chinese traditional medicine "he ji ju fang" and pharmacopoeia] (Jpn). Yakushigaku Zasshi. 1981;16:39–43.

Balap A, Lohidasan S, Sinnathambi A, Mahadik K. Herb-drug interaction of Andrographis paniculata (Nees) extract and andrographolide on pharmacokinetic and pharmacodynamic of naproxen in rats. J Ethnopharmacol. 2017;195:214–21.

Tang D, Chen K, Huang L, Li J. Pharmacokinetic properties and drug interactions of apigenin, a natural flavone. Expert Opin Drug Metab Toxicol. 2017;13:323–30.

Mao CG, Tao ZZ, Wan LJ, Han JB, Chen Z, et al. The efficacy of traditional Chinese medicine as an adjunctive therapy in nasopharyngeal carcinoma: a systematic review and meta-analysis. J BUON. 2014;19:540–8.

Chien CR, Su SY, Cohen L, Lin HW, Lee RT, et al. Use of Chinese medicine among survivors of nasopharyngeal carcinoma in Taiwan: a population-based study. Integr Cancer Ther. 2012;11:221–31.

Fayers P, Bottomley A, Group EQoL, Quality of Life U. Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer. Eur J Cancer. 2002;38 Suppl 4:S125–33.

Bjordal K, Hammerlid E, Ahlner-Elmqvist M, de Graeff A, Boysen M, et al. Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer quality of life questionnaire-H&N35. J Clin Oncol. 1999;17:1008–19.

Chie WC, Hong RL, Lai CC, Ting LL, Hsu MM. Quality of life in patients of nasopharyngeal carcinoma: validation of the Taiwan Chinese version of the EORTC QLQ-C30 and the EORTC QLQ-H&N35. Qual Life Res. 2003;12:93–8.

Hammerlid E, Taft C. Health-related quality of life in long-term head and neck cancer survivors: a comparison with general population norms. Br J Cancer. 2001;84:149–56.

de Graeff A, de Leeuw JR, Ros WJ, Hordijk GJ, Blijham GH, et al. Long-term quality of life of patients with head and neck cancer. Laryngoscope. 2000;110:98–106.

Bjordal K, Ahlner-Elmqvist M, Hammerlid E, Boysen M, Evensen JF, et al. A prospective study of quality of life in head and neck cancer patients. Part II: Longitudinal data. Laryngoscope. 2001;111:1440–52.

Carvalho AP, McNeely ML, Vital FM. Interventions for preventing and treating trismus in patients with head and neck cancer. Cochrane Database Syst Rev. 2016;8:CD012316.

Scherpenhuizen A, van Waes AM, Janssen LM, Van Cann EM, Stegeman I. The effect of exercise therapy in head and neck cancer patients in the treatment of radiotherapy-induced trismus: a systematic review. Oral Oncol. 2015;51:745–50.

Middel B, Stewart R, Bouma J, van Sonderen E, van den Heuvel WJ. How to validate clinically important change in health-related functional status. Is the magnitude of the effect size consistently related to magnitude of change as indicated by a global question rating? J Eval Clin Pract. 2001;7:399–410.

Eisbruch A, Kim HM, Terrell JE, Marsh LH, Dawson LA, et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;50:695–704.

Graff P, Lapeyre M, Desandes E, Ortholan C, Bensadoun RJ, et al. Impact of intensity-modulated radiotherapy on health-related quality of life for head and neck cancer patients: matched-pair comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys. 2007;67:1309–17.